[
  {
    "ts": null,
    "headline": "Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug Deal",
    "summary": "The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.",
    "url": "https://finnhub.io/api/news?id=092cefb055415a0f87518bef30883dd437bde038c768c86a7d6c0900aea55439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761950640,
      "headline": "Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug Deal",
      "id": 137294827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.",
      "url": "https://finnhub.io/api/news?id=092cefb055415a0f87518bef30883dd437bde038c768c86a7d6c0900aea55439"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Issues Statement in Response to Litigation",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
    "url": "https://finnhub.io/api/news?id=f532434f6a96ff02b2515eac1902cd506bf47902e8afe53d2d2519789f6d5265",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761949440,
      "headline": "Metsera Issues Statement in Response to Litigation",
      "id": 137294828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
      "url": "https://finnhub.io/api/news?id=f532434f6a96ff02b2515eac1902cd506bf47902e8afe53d2d2519789f6d5265"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk",
    "summary": "Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.  New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday.",
    "url": "https://finnhub.io/api/news?id=64ea665473cf07a60ca44bd53766eeda04aaf771bfb64c98286885400fb2ede4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761946090,
      "headline": "Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk",
      "id": 137294829,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.  New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday.",
      "url": "https://finnhub.io/api/news?id=64ea665473cf07a60ca44bd53766eeda04aaf771bfb64c98286885400fb2ede4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal",
    "summary": "Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.",
    "url": "https://finnhub.io/api/news?id=a615106b4cf3912b11eca66af3666cedf1b7a6d30bd7008465d9bbb7115d2933",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761946013,
      "headline": "Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal",
      "id": 137294830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.",
      "url": "https://finnhub.io/api/news?id=a615106b4cf3912b11eca66af3666cedf1b7a6d30bd7008465d9bbb7115d2933"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple pares gains with earnings from AI players to come",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=f71dd7ce2ec6ef6631512e643d8937c9c24821909027b57a9fe612fd64a8afb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761945147,
      "headline": "Earnings live: Amazon stock soars, Apple pares gains with earnings from AI players to come",
      "id": 137282600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=f71dd7ce2ec6ef6631512e643d8937c9c24821909027b57a9fe612fd64a8afb5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement",
    "summary": "NEW YORK, October 31, 2025--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.",
    "url": "https://finnhub.io/api/news?id=97c7499f253dc58f935cb5ed932e1b865e2d6c7a29d4e9daef1c4eb3b0c7fc72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761943020,
      "headline": "Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement",
      "id": 137294832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 31, 2025--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.",
      "url": "https://finnhub.io/api/news?id=97c7499f253dc58f935cb5ed932e1b865e2d6c7a29d4e9daef1c4eb3b0c7fc72"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition",
    "summary": "NEW YORK, October 31, 2025--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the \"HSR Act\"), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).",
    "url": "https://finnhub.io/api/news?id=5e977cfdb39319abf3402a07c87efdeeca8b4f8028ad8de45827f569784d708f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761940200,
      "headline": "Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition",
      "id": 137294833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 31, 2025--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the \"HSR Act\"), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).",
      "url": "https://finnhub.io/api/news?id=5e977cfdb39319abf3402a07c87efdeeca8b4f8028ad8de45827f569784d708f"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Pfizer Could Use White House Connections to Counter Novo Nordisk's Bid for Metsera",
    "summary": "Pfizer (PFE) could leverage its White House connections to counter Novo Nordisk's (NVO) bid for obes",
    "url": "https://finnhub.io/api/news?id=1e56e0a3d4826e42d047befe6cde171d037e8f563a8cb1868c6bd3e4f8ac4bd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761938335,
      "headline": "Market Chatter: Pfizer Could Use White House Connections to Counter Novo Nordisk's Bid for Metsera",
      "id": 137281336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) could leverage its White House connections to counter Novo Nordisk's (NVO) bid for obes",
      "url": "https://finnhub.io/api/news?id=1e56e0a3d4826e42d047befe6cde171d037e8f563a8cb1868c6bd3e4f8ac4bd9"
    }
  },
  {
    "ts": null,
    "headline": "Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window",
    "summary": "Corbus Pharmaceuticals Holdings pivots CRB-701 focus to rare cancers with promising early results. Click for key CRBP stock updates, risks and growth prospects.",
    "url": "https://finnhub.io/api/news?id=6015dc83c7c7609dbe30f9c6fd3b4f7a2553124fe0750808a6b9b30100175cd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761931723,
      "headline": "Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window",
      "id": 137282415,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221989856/image_2221989856.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Corbus Pharmaceuticals Holdings pivots CRB-701 focus to rare cancers with promising early results. Click for key CRBP stock updates, risks and growth prospects.",
      "url": "https://finnhub.io/api/news?id=6015dc83c7c7609dbe30f9c6fd3b4f7a2553124fe0750808a6b9b30100175cd2"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761908940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137277251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?",
    "summary": "Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.",
    "url": "https://finnhub.io/api/news?id=c74b1e5573dac770defc95b01b4e3f53ef73406f090982fa1d31efbbd49fb1df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761923220,
      "headline": "Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?",
      "id": 137279208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.",
      "url": "https://finnhub.io/api/news?id=c74b1e5573dac770defc95b01b4e3f53ef73406f090982fa1d31efbbd49fb1df"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs",
    "summary": "STORY: :: Novo Nordisk Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.That’s according to a LinkedIn post by CEO Mike Doustdar Friday. As jobs were slashed globally, he added that the pace of informing people varied according to local laws. It’s part of Doustdar’s restructuring drive which he launched last month. And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  :: Pfizer The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. The drugmakers are vying for access to its once-monthly GLP-1 injectable.Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. Metsera is one of several companies developing experimental weight-loss drugs.The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.That was over concerns it was not moving fast enough in the obesity market.",
    "url": "https://finnhub.io/api/news?id=038c78804c817adcd3cd069084a2da429170bd73fb73930a95fcc97e4b7a5cc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761920886,
      "headline": "Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs",
      "id": 137279023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "STORY: :: Novo Nordisk Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.That’s according to a LinkedIn post by CEO Mike Doustdar Friday. As jobs were slashed globally, he added that the pace of informing people varied according to local laws. It’s part of Doustdar’s restructuring drive which he launched last month. And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  :: Pfizer The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. The drugmakers are vying for access to its once-monthly GLP-1 injectable.Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. Metsera is one of several companies developing experimental weight-loss drugs.The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.That was over concerns it was not moving fast enough in the obesity market.",
      "url": "https://finnhub.io/api/news?id=038c78804c817adcd3cd069084a2da429170bd73fb73930a95fcc97e4b7a5cc1"
    }
  },
  {
    "ts": null,
    "headline": "Metsera (MTSR) Soars to All-Time High on Pfizer, Novo Billion-Dollar Bidding War",
    "summary": "We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. […]",
    "url": "https://finnhub.io/api/news?id=c292a2bfc0ade62ecffde55c41ed4427ced54b6b86ea7cad2341567029fa79d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761919386,
      "headline": "Metsera (MTSR) Soars to All-Time High on Pfizer, Novo Billion-Dollar Bidding War",
      "id": 137279210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. […]",
      "url": "https://finnhub.io/api/news?id=c292a2bfc0ade62ecffde55c41ed4427ced54b6b86ea7cad2341567029fa79d8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Faces Off With Novo Nordisk Over Metsera Bid",
    "summary": "U.S. drugmaker may leverage political ties as takeover battle intensifies",
    "url": "https://finnhub.io/api/news?id=acbd63c5b3deca0461a1cf998873ad82253eff5f8d37863077a94620a6a0518c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913508,
      "headline": "Pfizer Faces Off With Novo Nordisk Over Metsera Bid",
      "id": 137277405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "U.S. drugmaker may leverage political ties as takeover battle intensifies",
      "url": "https://finnhub.io/api/news?id=acbd63c5b3deca0461a1cf998873ad82253eff5f8d37863077a94620a6a0518c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
    "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
    "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913200,
      "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
      "id": 137277301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
      "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
    "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761907191,
      "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
      "id": 137277814,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/939034648/image_939034648.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Palantir, Advanced Micro Devices, Uber, Novo Nordisk and BP",
    "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=ca75cc1a3272c07276b5bbb55bf3c159466cba1ce23eeb2c052654aaca43fe95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761890421,
      "headline": "Stocks to watch next week: Palantir, Advanced Micro Devices, Uber, Novo Nordisk and BP",
      "id": 137275010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=ca75cc1a3272c07276b5bbb55bf3c159466cba1ce23eeb2c052654aaca43fe95"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Pfizer: “The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But […]",
    "url": "https://finnhub.io/api/news?id=510ad534daeb91c2b96897db2f87f359d1609dbc11c03ee33b5c5bbcd89a686c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761877814,
      "headline": "Jim Cramer on Pfizer: “The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There”",
      "id": 137275131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But […]",
      "url": "https://finnhub.io/api/news?id=510ad534daeb91c2b96897db2f87f359d1609dbc11c03ee33b5c5bbcd89a686c"
    }
  }
]